Agilent Technologies to Buy ACEA Biosciences for $250 Million
September 26 2018 - 7:12AM
Dow Jones News
By Colin Kellaher
Agilent Technologies Inc. (A) said it agreed to buy ACEA
Biosciences Inc., a developer of cell-analysis instruments for
life-science research and clinical diagnostics, for $250 million in
cash.
Agilent, a Santa Clara, Calif., provider of application-focused
solutions to the life-sciences, diagnostics and applied-chemical
markets, said the deal adds a differentiated portfolio and
capabilities in the fast-growing cell-analysis market.
ACEA, based in San Diego, has a large manufacturing and
research-and-development footprint in Hangzhou, China, Agilent
said.
Agilent entered the cell-analysis market in 2015 with its $235
million purchase of Seahorse Bioscience. The company in January
expanded its cell-analysis portfolio by acquiring Luxcel
Biosciences.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
September 26, 2018 06:57 ET (10:57 GMT)
Copyright (c) 2018 Dow Jones & Company, Inc.
Agilent Technologies (NYSE:A)
Historical Stock Chart
From Mar 2024 to Apr 2024
Agilent Technologies (NYSE:A)
Historical Stock Chart
From Apr 2023 to Apr 2024
